Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate

Eur J Cancer. 2018 May:95:109-111. doi: 10.1016/j.ejca.2018.01.086. Epub 2018 Feb 21.

¹ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. Electronic address: Chukwuka.Eze@med.uni-muenchen.de.
² Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
³ Department of Urology, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Munich, Germany.
⁴ Institute of Pathology, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany; DKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁵ Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, D-81377 Munich, Germany; DKTK, German Cancer Consortium, German Cancer Research Center (DKFZ), Heidelberg, Germany.

No abstract available

Keywords: Adenosquamous-cell carcinoma; Immune checkpoint inhibitor; Nivolumab; Prostate cancer; Radiotherapy.

Publication types